Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Livmoniplimab - AbbVie

Next Previous
Drug Profile

Livmoniplimab - AbbVie

Alternative Names: ABBV-151; ARGX-115; MHG-8

Latest Information Update: 09 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Catholic University of Louvain; Ludwig Institute for Cancer Research
  • Developer AbbVie
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action TGF-beta superfamily protein inhibitors; Transforming growth factor beta1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Liver cancer; Non-small cell lung cancer
  • Phase II Solid tumours; Urogenital cancer

Most Recent Events

  • 09 Mar 2026 CTP Push700370841: Updated KDM, missing locations added, dev T updated
  • 20 Dec 2024 Phase-II clinical trials in Urogenital cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV), (NCT06632951),
  • 09 Oct 2024 AbbVie plans a phase II trial for Urogenital cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in December 2024 (IV) (NCT06632951)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top